Investigating the mechanisms of drug sensitivity and resistance to targeted therapies for lung cancer.

Main Header
Go to Research

Featured Publication

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.

Published June 20, 2022
See all Publications

Aaron Hata, MD PhD, Principal Investigator


Our mission is to advance the development of new therapies for patients with lung cancer through scientific discovery of the molecular mechanisms of drug sensitivity and resistance, understanding tumor evolution during treatment, and identification of targetable vulnerabilities to guide investigation of novel therapeutic strategies.

We are a diverse group of physicians & scientists with expertise in cell biology, pharmacology, genetics, immunology and computational biology.

Meet the Team

News — November 18, 2022

Danielle Colucci

We say farewell to Danielle who will be attending a Software Bootcamp at General Assembly. Best wishes to you in your future endeavors – we will miss you!

Go to News

News — October 27, 2022


We are excited to report the results of this collaboration with Nuvalent at the 2022 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: NVL-655 shows activity against lorlatinib-resistant ALK NSCLC…

Go to News

We are looking for people to partner with us in our mission to improve treatments for patients with lung cancer.

Join Us Support Us


We are privileged to partner with a number of individuals and organizations who support our research. We are grateful for their dedication to helping us in the fight against lung cancer.